Table 3.
Excess risk and standardised incidence ratios of prostate cancer in 62 753 men with a first diagnosis of acute urinary retention, stratified by patient characteristics
| Characteristics | Follow-up period | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 to <3 months | 3 to <12 months | 1 to 5 years | |||||||||
| O/E | Excess risk per 1000 PY (95% CI) | SIR (95% CI) | O/E | Excess risk per 1000 PY (95% CI) | SIR (95% CI) | O/E | Excess risk per 1000 PY (95% CI) | SIR (95% CI) | |||
| Overall | 3198/93 | 218 (214 to 221) | 34.5 (33.3 to 35.7) | 1035/244 | 21 (20 to 23) | 4.2 (4.0 to 4.5) | 984/896 | 1 (0 to 2) | 1.1 (1.0 to 1.2) | ||
| Age (years): | |||||||||||
| 50-64 | 448/6 | 163 (156 to 170) | 74.5 (67.8 to 81.8) | 138/19 | 16 (13 to 18) | 7.4 (6.2 to 8.8) | 149/113 | 1 (−1 to 3) | 1.3 (1.1 to 1.5) | ||
| 65-79 | 1772/48 | 256 (251 to 261) | 37.0 (35.3 to 38.7) | 544/132 | 23 (21 to 25) | 4.1 (3.8 to 4.5) | 497/532 | −1 (−2 to 1) | 0.9 (0.9 to 1.0) | ||
| ≥80 | 978/39 | 194 (189 to 200) | 25.2 (23.7 to 26.9) | 353/94 | 22 (19 to 25) | 3.8 (3.4 to 4.2) | 338/251 | 3 (0 to 5) | 1.3 (1.2 to 1.5) | ||
| Calendar period: | |||||||||||
| 1995-98 | 411/7 | 249 (239 to 259) | 57.3 (51.9 to 63.1) | 128/19 | 26 (21 to 31) | 6.8 (5.7 to 8.1) | 115/83 | 2 (−1 to 5) | 1.4 (1.2 to 1.7) | ||
| 1999-2003 | 664/16 | 233 (225 to 240) | 42.3 (39.2 to 45.7) | 231/42 | 26 (22 to 30) | 5.5 (4.8 to 6.3) | 226/190 | 1 (−1 to 4) | 1.2 (1.0 to 1.4) | ||
| 2004-08 | 782/24 | 234 (227 to 241) | 31.9 (29.7 to 34.2) | 245/64 | 22 (18 to 25) | 3.8 (3.4 to 4.3) | 235/250 | 0 (−3 to 2) | 0.9 (0.8 to 1.1) | ||
| 2009-13 | 725/25 | 197 (190 to 203) | 29.2 (27.2 to 31.5) | 244/64 | 19 (16 to 22) | 3.8 (3.3 to 4.3) | 279/254 | 1 (−1 to 3) | 1.1 (1.0 to 1.2) | ||
| 2014-17 | 616/21 | 194 (187 to 201) | 30.0 (27.7 to 32.4) | 187/54 | 16 (13 to 19) | 3.4 (3.0 to 4.0) | 129/119 | 1 (−2 to 3) | 1.1 (0.9 to 1.3) | ||
| Type of urinary retention*: | |||||||||||
| Primary | 2469/72 | 212 (208 to 216) | 34.2 (32.8 to 35.6) | 856/193 | 22 (20 to 24) | 4.4 (4.2 to 4.8) | 830/734 | 1 (−0 to 2) | 1.1 (1.1 to 1.2) | ||
| Secondary | 729/20 | 239 (232 to 246) | 35.6 (33.1 to 38.3) | 179/51 | 17 (14 to 21) | 3.5 (3.0 to 4.1) | 154/162 | 0 (−3 to 2) | 0.9 (0.8 to 1.1) | ||
| Comorbidities | |||||||||||
| Urogenital disease | |||||||||||
| No | 1936/44 | 273 (268 to 278) | 44.1 (42.2 to 46.2) | 545/114 | 24 (22 to 26) | 4.8 (4.4 to 5.2) | 424/413 | 0 (−1 to 2) | 1.0 (0.9 to 1.1) | ||
| Yes | 1262/49 | 165 (161 to 169) | 25.8 (24.4 to 27.3) | 490/130 | 19 (17 to 21) | 3.8 (3.5 to 4.1) | 560/483 | 1 (−0 to 3) | 1.2 (1.1 to 1.3) | ||
| Neurological disease | |||||||||||
| No | 2720/67 | 253 (249 to 257) | 40.8 (39.3 to 42.3) | 856/177 | 25 (23 to 26) | 4.8 (4.5 to 5.2) | 800/686 | 1 (−0 to 2) | 1.2 (1.1 to 1.3) | ||
| Yes | 478/26 | 119 (114 to 124) | 18.4 (16.8 to 20.1) | 179/67 | 11 (9 to 14) | 2.7 (2.3 to 3.1) | 184/211 | −1 (−3 to 1) | 0.9 (0.8 to 1.0) | ||
| Diabetes | |||||||||||
| No | 2945/80 | 231 (227 to 235) | 36.9 (35.6 to 38.2) | 945/211 | 23 (21 to 24) | 4.5 (4.2 to 4.8) | 890/792 | 1 (−0 to 2) | 1.1 (1.1 to 1.2) | ||
| Yes | 253/13 | 128 (120 to 136) | 19.7 (17.4 to 22.3) | 90/33 | 12 (8 to 16) | 2.7 (2.2 to 3.4) | 94/104 | −1 (−4 to 2) | 0.9 (0.7 to 1.1) | ||
| Charlson comorbidity index score: | |||||||||||
| 0 | 1964/39 | 292 (286 to 297) | 49.9 (47.8 to 52.2) | 578/108 | 26 (24 to 29) | 5.4 (4.9 to 5.8) | 585/462 | 2 (0 to 3) | 1.3 (1.2 to 1.4) | ||
| 1-2 | 1007/37 | 179 (174 to 184) | 27.0 (25.4 to 28.7) | 363/97 | 19 (17 to 22) | 3.8 (3.4 to 4.2) | 324/327 | 0 (−2 to 2) | 1.0 (0.9 to 1.1) | ||
| ≥3 | 227/16 | 93 (87 to 99) | 14.1 (12.3 to 16.1) | 94/39 | 10 (7 to 13) | 2.4 (1.9 to 2.9) | 75/108 | −2 (−5 to 0) | 0.7 (0.5 to 0.9) | ||
O/E=observed/expected; PY=person years; SIR=standardised incidence ratio.
*
Primary indicates acute urinary retention as a primary diagnosis or, in men, a diagnosis secondary to benign prostatic hyperplasia. All other cases were classified as secondary acute urinary retention.